MedTrace Logo

Evaluation of the Clinical Benefit of the Hearing Aids Tinnitus Feature.

NCT05292534 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-07-05

Study results available
· View outcomes & findings →

Summary

Participants with hearing loss and Tinnitus will wear hearing aids with amplification-only or with an added sound, and have their tinnitus level evaluated before and after intervention.

Conditions

  • Hearing Loss, Sensorineural
  • Tinnitus

Interventions

DEVICE

hearing aid amplification

Hearing aid will be fit to prescribed participant hearing loss.

DEVICE

hearing aid amplification with an added sound

Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated.

Sponsors & Collaborators

  • State University of New York at Buffalo

    collaborator OTHER

  • Sonova AG

    lead INDUSTRY

Principal Investigators

  • Wei Sun, Ph.D. · State University of New York at Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-09-20
Completion
2023-09-20
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05292534 on ClinicalTrials.gov